- Page 1 and 2: METHODS IN MOLECULAR BIOLOGY 333 T
- Page 3 and 4: M E T H O D S I N M O L E C U L A R
- Page 5: © 2006 Humana Press Inc. 999 River
- Page 9 and 10: viii Contents 14 Real-Time Quantita
- Page 11 and 12: x Contributors PETER MARK ANTHONY H
- Page 13 and 14: 2 Callaghan and Bradley Table 1 Und
- Page 15 and 16: 4 Callaghan and Bradley 1.2. Determ
- Page 17 and 18: 6 Callaghan and Bradley kidney tran
- Page 19 and 20: 8 Callaghan and Bradley Table 3 Maa
- Page 21 and 22: 10 Callaghan and Bradley of pediatr
- Page 23 and 24: 12 Callaghan and Bradley Table 4 Ad
- Page 25 and 26: 14 Callaghan and Bradley adhesion m
- Page 27 and 28: 16 Callaghan and Bradley HLA compat
- Page 29 and 30: 18 Callaghan and Bradley Fig. 3. Ca
- Page 31 and 32: 20 Callaghan and Bradley 9. Harihar
- Page 33 and 34: 22 Callaghan and Bradley 42. Cho, Y
- Page 35 and 36: 24 Callaghan and Bradley 74. Matas,
- Page 37 and 38: 26 Callaghan and Bradley 101. Kazor
- Page 40 and 41: Transplantation Immunology
- Page 42 and 43: Status of Liver Transplantation 29
- Page 44 and 45: Status of Liver Transplantation 31
- Page 46 and 47: Status of Liver Transplantation 33
- Page 48 and 49: Status of Liver Transplantation 35
- Page 50 and 51: Status of Liver Transplantation 37
- Page 52 and 53: Status of Liver Transplantation 39
- Page 54 and 55: Status of Liver Transplantation 41
- Page 56 and 57:
Status of Liver Transplantation 43
- Page 58 and 59:
Status of Liver Transplantation 45
- Page 60 and 61:
Clinical Islet Cell Transplantation
- Page 62 and 63:
Clinical Islet Cell Transplantation
- Page 64 and 65:
Clinical Islet Cell Transplantation
- Page 66 and 67:
Clinical Islet Cell Transplantation
- Page 68 and 69:
Clinical Islet Cell Transplantation
- Page 70 and 71:
Clinical Islet Cell Transplantation
- Page 72 and 73:
Clinical Islet Cell Transplantation
- Page 74 and 75:
Clinical Islet Cell Transplantation
- Page 76 and 77:
Clinical Islet Cell Transplantation
- Page 78 and 79:
Clinical Islet Cell Transplantation
- Page 80 and 81:
Clinical Islet Cell Transplantation
- Page 82 and 83:
Clinical Islet Cell Transplantation
- Page 84 and 85:
Clinical Islet Cell Transplantation
- Page 86 and 87:
Clinical Islet Cell Transplantation
- Page 88 and 89:
Clinical Islet Cell Transplantation
- Page 90 and 91:
Clinical Islet Cell Transplantation
- Page 92 and 93:
Clinical Islet Cell Transplantation
- Page 94 and 95:
Clinical Islet Cell Transplantation
- Page 96 and 97:
Clinical Islet Cell Transplantation
- Page 98 and 99:
Clinical Islet Cell Transplantation
- Page 100 and 101:
Clinical Islet Cell Transplantation
- Page 102 and 103:
Clinical Islet Cell Transplantation
- Page 104 and 105:
Clinical Islet Cell Transplantation
- Page 106 and 107:
Clinical Islet Cell Transplantation
- Page 108 and 109:
Clinical Islet Cell Transplantation
- Page 110 and 111:
Clinical Islet Cell Transplantation
- Page 112 and 113:
Clinical Islet Cell Transplantation
- Page 114 and 115:
Clinical Islet Cell Transplantation
- Page 116:
Clinical Islet Cell Transplantation
- Page 119 and 120:
106 Glanville International guideli
- Page 121 and 122:
108 Glanville 2. Long-Term Outcomes
- Page 123 and 124:
110 Glanville 2.2. Morbidity 2.2.1.
- Page 125 and 126:
112 Glanville risk for an individua
- Page 127 and 128:
114 Glanville Our recent review rec
- Page 129 and 130:
116 Glanville tioning (95), the pre
- Page 131 and 132:
118 Glanville 3. Bronchiolitis Obli
- Page 133 and 134:
120 Glanville the time of entry to
- Page 135 and 136:
122 Glanville 4. Whyte, R. I., Robb
- Page 137 and 138:
124 Glanville 35. Hosenpud, J. D.,
- Page 139 and 140:
126 Glanville 69. Burke, C. M., Gla
- Page 141 and 142:
128 Glanville 99. Resnikoff, P. M.
- Page 143 and 144:
130 Glanville 130. Orens, J. B., Bo
- Page 145 and 146:
132 Hornick and Rose diagnosis and
- Page 147 and 148:
134 Hornick and Rose cyclosporine a
- Page 149 and 150:
136 Hornick and Rose A number of ex
- Page 151 and 152:
138 Hornick and Rose immune respons
- Page 153 and 154:
140 Hornick and Rose 13. Bieber, C.
- Page 155 and 156:
142 Hornick and Rose 46. Sarris, G.
- Page 157 and 158:
144 Hornick and Rose 77. Shi, C., L
- Page 159 and 160:
146 Hornick Any discussion pertaini
- Page 161 and 162:
148 Hornick 2. Observations of Dire
- Page 163 and 164:
150 150 Hornick
- Page 165 and 166:
152 Hornick of this in graft reject
- Page 167 and 168:
154 Hornick 14. Austyn, J. and Lars
- Page 169 and 170:
156 Hornick 44. Taylor, D., Ibrahim
- Page 171 and 172:
158 Sheldon and Poulton The evoluti
- Page 173 and 174:
160 Sheldon and Poulton mismatch ma
- Page 175 and 176:
162 Sheldon and Poulton Fig. 1. HLA
- Page 177 and 178:
164 Sheldon and Poulton Fig. 2. The
- Page 179 and 180:
166 Sheldon and Poulton Early antib
- Page 181 and 182:
168 Sheldon and Poulton tier allowi
- Page 183 and 184:
170 Sheldon and Poulton may be carr
- Page 185 and 186:
172 Sheldon and Poulton 8. Vartdal,
- Page 187 and 188:
174 Sheldon and Poulton ciation. (1
- Page 189 and 190:
176 Lawson gov.uk/genetics/gtac) ad
- Page 191 and 192:
178 Lawson ing of Fas has been achi
- Page 193 and 194:
180 Lawson contain sequences requir
- Page 195 and 196:
182 Table 1 Characteristics of Comm
- Page 197 and 198:
184 Lawson 5.1. Oncoretroviruses To
- Page 199 and 200:
186 Lawson The genome is functional
- Page 201 and 202:
188 Lawson 8. Herpes Simplex Virus-
- Page 203 and 204:
190 Lawson 10. de Perrot, M., Fisch
- Page 205 and 206:
192 Lawson tion inhibits posttransp
- Page 207 and 208:
194 Lawson 67. Miyoshi, H., Takahas
- Page 209 and 210:
196 Lawson 98. Kumar-Singh, R. and
- Page 211 and 212:
198 Lawson 127. Ali, R. R., Reichel
- Page 213 and 214:
Nonviral Vectors 201 9 Nonviral Vec
- Page 215 and 216:
Nonviral Vectors 203 Although publi
- Page 217 and 218:
205 Fig. 1. Structures of commonly
- Page 219 and 220:
Nonviral Vectors 207 Fig. 2. Basic
- Page 221 and 222:
209 α-CD3 antibody Polylysine, PEI
- Page 223 and 224:
Nonviral Vectors 211 Toxicity has b
- Page 225 and 226:
Nonviral Vectors 213 To address the
- Page 227 and 228:
Nonviral Vectors 215 porating a nuc
- Page 229 and 230:
Nonviral Vectors 217 12. Yang, J.-P
- Page 231 and 232:
Nonviral Vectors 219 43. Hara, T.,
- Page 233 and 234:
Nonviral Vectors 221 ponents, exten
- Page 235 and 236:
Nonviral Vectors 223 107. Wu, G. Y.
- Page 237:
Nonviral Vectors 225 137. Schachtsc
- Page 240 and 241:
228 Smith and Rose greater sensitiv
- Page 242 and 243:
230 Smith and Rose passed through t
- Page 244 and 245:
232 Smith and Rose but non-HLA anti
- Page 246 and 247:
234 Smith and Rose bronchiolitis ob
- Page 248 and 249:
236 Smith and Rose interest in AECA
- Page 250 and 251:
238 Smith and Rose Recent studies s
- Page 252 and 253:
240 Smith and Rose vimentin antibod
- Page 254 and 255:
242 Smith and Rose 14. Jaramillo, A
- Page 256 and 257:
244 Smith and Rose 42. Fedoseyeva,
- Page 259 and 260:
Using Abs to Reprogram the Immune S
- Page 261 and 262:
Using Abs to Reprogram the Immune S
- Page 263 and 264:
Using Abs to Reprogram the Immune S
- Page 265 and 266:
Using Abs to Reprogram the Immune S
- Page 267 and 268:
Using Abs to Reprogram the Immune S
- Page 269 and 270:
Using Abs to Reprogram the Immune S
- Page 271 and 272:
Using Abs to Reprogram the Immune S
- Page 273 and 274:
Using Abs to Reprogram the Immune S
- Page 275 and 276:
Using Abs to Reprogram the Immune S
- Page 277 and 278:
Using Abs to Reprogram the Immune S
- Page 279 and 280:
Using Abs to Reprogram the Immune S
- Page 281 and 282:
270 Hernandez-Fuentes and Salama no
- Page 283 and 284:
272 Hernandez-Fuentes and Salama Fi
- Page 285 and 286:
274 Hernandez-Fuentes and Salama br
- Page 287 and 288:
276 Hernandez-Fuentes and Salama Fi
- Page 289 and 290:
278 Hernandez-Fuentes and Salama Fi
- Page 291 and 292:
280 Hernandez-Fuentes and Salama us
- Page 293 and 294:
282 Hernandez-Fuentes and Salama th
- Page 295 and 296:
284 Hernandez-Fuentes and Salama gr
- Page 297 and 298:
286 Hernandez-Fuentes and Salama 25
- Page 299 and 300:
288 Hernandez-Fuentes and Salama ep
- Page 301 and 302:
290 Hernandez-Fuentes and Salama 80
- Page 303 and 304:
292 McGregor and De Souza novel gen
- Page 305 and 306:
294 McGregor and De Souza Fig. 1. A
- Page 307 and 308:
296 McGregor and De Souza to detect
- Page 309 and 310:
298 McGregor and De Souza Fig. 2. L
- Page 311 and 312:
300 McGregor and De Souza Fig. 3. T
- Page 313 and 314:
302 McGregor and De Souza 7. Wasing
- Page 315 and 316:
304 McGregor and De Souza 36. Golds
- Page 317 and 318:
306 Felkin et al. 2. Real-Time PCR
- Page 319 and 320:
308 Felkin et al. Fig. 1. Detection
- Page 321 and 322:
310 Felkin et al. Fig. 2. (continue
- Page 323 and 324:
312 Felkin et al. Fig. 3. Effect of
- Page 325 and 326:
314 Felkin et al. the sensitivity o
- Page 327 and 328:
316 Felkin et al. Fig. 5. Determina
- Page 329 and 330:
318 Felkin et al. 28). Such strateg
- Page 331 and 332:
320 Felkin et al. Fig. 6. Steps inv
- Page 333 and 334:
322 Table 5 (Continued) Examples of
- Page 335 and 336:
324 Felkin et al. Fig. 7. Autocalli
- Page 337 and 338:
326 Felkin et al. 4. Conclusion Sin
- Page 339 and 340:
328 Felkin et al. 25. Relative quan
- Page 341 and 342:
330 Felkin et al. 55. He, J. Q., Ga
- Page 343 and 344:
332 Hicks et al. factors including
- Page 345 and 346:
334 Hicks et al. both globally (14)
- Page 347 and 348:
336 Hicks et al. suggest that donor
- Page 349 and 350:
338 Hicks et al. Fig. 1. Crystal Ci
- Page 351 and 352:
340 Hicks et al. Regular airway suc
- Page 353 and 354:
342 Hicks et al. Hypothermia marked
- Page 355 and 356:
344 Hicks et al. Table 2 Compositio
- Page 357 and 358:
346 Hicks et al. 3.2.2.2. CA 2+ OVE
- Page 359 and 360:
348 Hicks et al. 3.3.1. Electrolyte
- Page 361 and 362:
350 Hicks et al. to 6 h. Experiment
- Page 363 and 364:
352 Hicks et al. 4.1.1. Flushing Co
- Page 365 and 366:
354 Hicks et al. several investigat
- Page 367 and 368:
356 Hicks et al. Concerns regarding
- Page 369 and 370:
358 Hicks et al. Table 3 Potential
- Page 371 and 372:
360 Hicks et al. 19. Masson, F., Th
- Page 373 and 374:
362 Hicks et al. 50. Wheeldon, D. R
- Page 375 and 376:
364 Hicks et al. 78. Changani, K. K
- Page 377 and 378:
366 Hicks et al. 106. Cropper, J. R
- Page 379 and 380:
368 Hicks et al. 135. Haniuda, M.,
- Page 381 and 382:
370 Hicks et al. 164. Lick, S. D.,
- Page 383 and 384:
372 Hicks et al. 196. Aitchison, J.
- Page 386 and 387:
Pharmacological Manipulation of the
- Page 388 and 389:
Pharmacological Manipulation of the
- Page 390 and 391:
Pharmacological Manipulation of the
- Page 392 and 393:
381 Table 3 Comparison of Cyclospor
- Page 394 and 395:
Pharmacological Manipulation of the
- Page 396 and 397:
Pharmacological Manipulation of the
- Page 398 and 399:
Pharmacological Manipulation of the
- Page 400 and 401:
Pharmacological Manipulation of the
- Page 402 and 403:
Pharmacological Manipulation of the
- Page 404 and 405:
Pharmacological Manipulation of the
- Page 406 and 407:
Pharmacological Manipulation of the
- Page 408 and 409:
Pharmacological Manipulation of the
- Page 410:
Pharmacological Manipulation of the
- Page 413 and 414:
402 Soleimani and Shi as the likely
- Page 415 and 416:
404 Soleimani and Shi 3. Cardiac Al
- Page 417 and 418:
406 Soleimani and Shi Fig. 2. Surgi
- Page 419 and 420:
408 Soleimani and Shi can be averte
- Page 421 and 422:
410 Soleimani and Shi Fig. 3. Photo
- Page 423 and 424:
412 Soleimani and Shi A primate aor
- Page 425 and 426:
414 Soleimani and Shi tinuous study
- Page 427 and 428:
416 Soleimani and Shi 5. Lumbar vei
- Page 429 and 430:
418 Soleimani and Shi 11. Ono, K.,
- Page 431 and 432:
420 Soleimani and Shi 40. Russell,
- Page 433 and 434:
422 Soleimani and Shi 69. Raisanen-
- Page 436:
METHODS IN MOLECULAR BIOLOGY • 3